Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. - 20. (Canceled)

21. (Currently amended) A pharmaceutical composition for preventing ~~or treating~~ a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of ~~claim 1~~ **the formula (I):**

A-Q-D-E-G-J-X

wherein:

A is selected from the group consisting of:

$-C(=NR^2)N(R^2,R^3)$; and

phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, -CN, $-C(=O)-N(R^2, R^3)$, $-NO_2$, $-SO_2N(R^2, R^3)$, $-SO_2R^2$, $-(CH_2)_mNR^2R^3$, $-(CH_2)_m-C(=NR^3)-R^2$, $-(CH_2)_m-C(=NR^2)-N(R^2,R^3)$, $-(CH_2)_m-N(R^2)-C(=NR^2)-N(R^2,R^3)$, $-(CH_2)_mNR^2-C_{3-6}$heterocyclics, C_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl, $-CF_3$, $-OR^2$, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C_1-C_4-alkyl, -CN C_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl and $-NO_2$;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H, -C_{1-6}alkyl, -C_{1-6}alkyloxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl and -C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-OH, -CN, -CF_3 and -NO_2;

m is an integer of 0-2;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

halo, -C_{1-6}alkyl, -C_{1-6}alkyloxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-OH, -CN, -NO_2, -$(CH_2)_n$-N(-R^{2a}, -R^{3a}), -$S(=O)_2$-N(-R^{2a}, -R^{3a}), -$S(=O)_2$-R^{2a}, -CF_3, -$(CH_2)_n$-OR^{2a}, -C(=O)-O-R^{2a}, -C(=O)-N(-R^{2a}, -R^{3a}), -C(=NH)-N(-R^{2a}, -R^{3a}), -C(=NMe)-N(-R^{2a}, -R^{3a}), 2-imidazolin-2-yl, 1-methyl-2-imidazolin-2-yl and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S and -C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the aromatic heterocyclic ring and the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -CN, -CF_3 and -NO_2;

n is an integer of 0-2;

R^{2a} and R^{3a} are independently selected from the group consisting of:

-H, -C_{1-6}alkyl, -C_{1-6}alkyloxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl and -C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo,

-C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-OH, -CN, -CF_3 and -NO_2;

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

halo, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl, -C_{1-4}alkyl-C(=O)-OH, -CN, -NO_2, -$S(=O)_2$-OH, -N(-R^{2b}, -R^{3b}), -C(=O)-N(-R^{2b}, -R^{3b}), -$S(=O)_2$-N(-R^{2b}, -R^{3b}),-$S(=O)_2$-R^{2b}, -CF_3, -O-R^{2b}, -O-CH_2-CH_2-O-R^{2b}, -O-CH_2-C(=O)-O-R^{2b}, -N(-R^{2b})-CH_2-CH_2-O-R^{2b}, -N(-CH_2-CH_2-O-R^{2b})$_2$, -N(-R^{2b})-C(=O)-R^{3b}, -N(-R^{2b})-$S(=O)_2$-R^{3b}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S substituted with 0-4 $R^{1b'}$ groups;

each R^{2b} and R^{3b} is a member independently selected from the group consisting of:

-H, -C_{1-6}alkyl, -C_{1-6}alkyloxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl and -C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-O^-, -CN, -CF_3 and -NO_2;

each $R^{1b'}$ is a member independently selected from the group consisting of:

halo, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl, -C_{1-4}alkyl-C(=O)-OH, -CN, -NO_2, -$S(=O)_2$-OH, -N(-$R^{2b'}$, -$R^{3b'}$), -C(=O)-N(-$R^{2b'}$, -$R^{3b'}$), -$S(=O)_2$-N(-$R^{2b'}$, -$R^{3b'}$), -$S(=O)_2$-$R^{2b'}$, -CF_3, -O-$R^{2b'}$, -O-CH_2-CH_2-O-$R^{2b'}$, -O-CH_2-C(=O)-O-$R^{2b'}$, -N(-$R^{2b'}$)-CH_2-CH_2-O-$R^{2b'}$, -N(-CH_2-CH_2-O-$R^{2b'}$)$_2$, -N(-$R^{2b'}$)-C(=O)-$R^{3b'}$ and -N(-$R^{2b'}$)-$S(=O)_2$-$R^{3b'}$;

each $R^{2b'}$ and $R^{3b'}$ are independently selected from the group consisting of:

-H, -C_{1-6}alkyl, -C_{1-6}alkoxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl and –C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloakyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-OH, -CN, -CF3 and -NO_2;

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, -CF_3, -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl, -C_{1-4}alkyl-C(=O)-OH, -CF_3, -CN, -NO_2, -$(CH_2)_z$-N(-R^{2c}, -R^{3c}), -C(=O)-N(-R^{2c}, -R^{3c}), -C(=NH)-N(-R^{2c}, -R^{3c}), -C(=NMe)-N(-R^{2c}, -R^{3c}), -$S(=O)_2$-N(-R^{2c}, -R^{3c}), -$S(=O)_2$-R^{2c}, -$S(=O)_2$-O H, -CF_3, -O-R^{2c}, -O(-$CH_2)_z$-O-R^{2c}, -O(-$CH_2)_z$-C(=O)-O-R^{2c}, -N(-R^{2c}), -O(-$CH_2)_z$-O-R^{2c}, -N[(-$CH_2)_z$-O-R^{2c}]$_2$, -$(CH_2)_z$-N(-R^{2c})-C(=O)-R^{3c}, -$(CH_2)_z$-N(-R^{2c})-$S(=O)_2$-R^{3c}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, -C_{1-6}alkyl, -C_{1-6}alkyloxy, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-6}alkylC_{3-8}cycloalkyl and -C_{0-6}alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, -C_{1-4}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, -C_{3-8}cycloalkyl, -C_{0-4}alkylC_{3-8}cycloalkyl, -$S(=O)_2$-OH, -CN, -CF_3 and -NO_2;

and all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

22. (Currently amended) A method for preventing ~~or treating~~ a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of ~~claim 1~~ **the formula (I):**

A-Q-D-E-G-J-X

wherein:

A is selected from the group consisting of:

$-C(=NR^2)N(R^2,R^3)$; and

phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, -CN, $-C(=O)-N(R^2, R^3)$, $-NO_2$, $-SO_2N(R^2, R^3)$, $-SO_2R^2$, $-(CH_2)_mNR^2R^3$, $-(CH_2)_m-C(=NR^3)-R^2$, $-(CH_2)_m-C(=NR^2)-N(R^2,R^3)$, $-(CH_2)_m-N(R^2)-C(=NR^2)-N(R^2,R^3)$, $-(CH_2)_mNR^2-C_{3-6}$heterocyclics, C_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl, $-CF_3$, $-OR^2$, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S, wherein from 1-4 hydrogen atoms on the heterocyclic system may be independently replaced with a member selected from the group consisting of halo, C_1-C_4-alkyl, -CN C_{1-4}alkyl, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl and $-NO_2$;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H, $-C_{1-6}$alkyl, $-C_{1-6}$alkyloxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-S(=O)_2-OH$, -CN, $-CF_3$ and $-NO_2$;

m is an integer of 0-2;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

halo, $-C_{1-6}$alkyl, $-C_{1-6}$alkyloxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl, $-S(=O)_2-OH$, $-CN$, $-NO_2$, $-(CH_2)_n-N(-R^{2a}, -R^{3a})$, $-S(=O)_2-N(-R^{2a}, -R^{3a})$, $-S(=O)_2-R^{2a}$, $-CF_3$, $-(CH_2)_n-OR^{2a}$, $-C(=O)-O-R^{2a}$, $-C(=O)-N(-R^{2a}, -R^{3a})$, $-C(=NH)-N(-R^{2a}, -R^{3a})$, $-C(=NMe)-N(-R^{2a}, -R^{3a})$, 2-imidazolin-2-yl, 1-methyl-2-imidazolin-2-yl and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the aromatic heterocyclic ring and the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-CN$, $-CF_3$ and $-NO_2$;

n is an integer of 0-2;

R^{2a} and R^{3a} are independently selected from the group consisting of:

$-H$, $-C_{1-6}$alkyl, $-C_{1-6}$alkyloxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-S(=O)_2-OH$, $-CN$, $-CF_3$ and $-NO_2$;

E is $-NH-C(=O)-$;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

halo, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl, $-C_{1-4}$alkyl-C(=O)-OH, -CN, $-NO_2$, $-S(=O)_2$-OH, $-N(-R^{2b}, -R^{3b})$, $-C(=O)-N(-R^{2b}, -R^{3b})$, $-S(=O)_2-N(-R^{2b}, -R^{3b})$,$-S(=O)_2-R^{2b}$, $-CF_3$, $-O-R^{2b}$, $-O-CH_2-CH_2-O-R^{2b}$, $-O-CH_2-C(=O)-O-R^{2b}$, $-N(-R^{2b})-CH_2-CH_2-O-R^{2b}$, $-N(-CH_2-CH_2-O-R^{2b})_2$, $-N(-R^{2b})-C(=O)-R^{3b}$, $-N(-R^{2b})-S(=O)_2-R^{3b}$, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S substituted with 0-4 $R^{1b'}$ groups;

each R^{2b} and R^{3b} is a member independently selected from the group consisting of:

-H, $-C_{1-6}$alkyl, $-C_{1-6}$alkyloxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-S(=O)_2-O^-$, -CN, $-CF_3$ and $-NO_2$;

each $R^{1b'}$ is a member independently selected from the group consisting of:

halo, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl, $-C_{1-4}$alkyl-C(=O)-OH, -CN, $-NO_2$, $-S(=O)_2$-OH, $-N(-R^{2b'}, -R^{3b'})$, $-C(=O)-N(-R^{2b'}, -R^{3b'})$, $-S(=O)_2-N(-R^{2b'}, -R^{3b'})$, $-S(=O)_2-R^{2b'}$, $-CF_3$, $-O-R^{2b'}$, $-O-CH_2-CH_2-O-R^{2b'}$, $-O-CH_2-C(=O)-O-R^{2b'}$, $-N(-R^{2b'})-CH_2-CH_2-O-R^{2b'}$, $-N(-CH_2-CH_2-O-R^{2b'})_2$, $-N(-R^{2b'})-C(=O)-R^{3b'}$ and $-N(-R^{2b'})-S(=O)_2-R^{3b'}$;

each $R^{2b'}$ and $R^{3b'}$ are independently selected from the group consisting of:

-H, $-C_{1-6}$alkyl, $-C_{1-6}$alkoxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloakyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-S(=O)_2$-OH, -CN, -CF3 and $-NO_2$;

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, $-CF_3$, $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl, $-C_{1-4}$alkyl-C(=O)-OH, $-CF_3$, -CN, $-NO_2$, $-(CH_2)_z$-N($-R^{2c}$, $-R^{3c}$), -C(=O)-N($-R^{2c}$, $-R^{3c}$), -C(=NH)-N($-R^{2c}$, $-R^{3c}$), -C(=NMe)-N($-R^{2c}$, $-R^{3c}$), $-S(=O)_2$-N($-R^{2c}$, $-R^{3c}$), $-S(=O)_2-R^{2c}$, $-S(=O)_2$-O H, $-CF_3$, $-O-R^{2c}$, $-O(-CH_2)_z$-O-R^{2c}, $-O(-CH_2)_z$-C(=O)-O-R^{2c}, -N($-R^{2c}$), $-O(-CH_2)_z$-O-R^{2c}, $-N[(-CH_2)_z$-O-$R^{2c}]_2$, $-(CH_2)_z$-N($-R^{2c}$)-C(=O)-R^{3c}, $-(CH_2)_z$-N($-R^{2c}$)-$S(=O)_2-R^{3c}$, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, $-C_{1-6}$alkyl, $-C_{1-6}$alkyloxy, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-6}$alkylC_{3-8}cycloalkyl and $-C_{0-6}$alkyl-(carbocyclic aryl), wherein from 0-4 hydrogen atoms on the ring atoms of the carbocyclic aryl moiety may be independently replaced with a member selected from the group consisting of halo, $-C_{1-4}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, $-C_{3-8}$cycloalkyl, $-C_{0-4}$alkylC_{3-8}cycloalkyl, $-S(=O)_2$-OH, -CN, $-CF_3$ and $-NO_2$;

and all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

23. (Currently amended) The method of claim **22 6**, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous

thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.

24. (Canceled)

25. (Currently amended) A pharmaceutical composition **of claim 21** ~~**for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 2**~~

wherein:

A is phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, C_{1-4}alkyl, -CN, -C(=O)-N(R^2, R^3), -NO_2, -SO_2N(R^2, R^3), -SO_2R^2, -$(CH_2)_m$$NR^2R^3$, -$(CH_2)_m$-C(=$NR^3$)-$R^2$, -$(CH_2)_m$-C(=$NR^2$)-N($R^2$,$R^3$), -$(CH_2)_m$-N($R^2$)-C(=$NR^2$)-N($R^2$,$R^3$), -$(CH_2)_m$$NR^2$-$C_{3-6}$heterocyclics, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl, -CF_3, -OR^2, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{0-4}alkyl-(carbocyclic aryl);

m is an integer of 0-2;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

halo, -C_{1-4}alkyl, -CN, -NO_2, -$(CH_2)_n$-N(-R^{2a}, -R^{3a}), -S(=O)$_2$-N(-R^{2a}, -R^{3a}), -S(=O)$_2$-R^{2a}, -CF_3, -$(CH_2)_n$-OR^{2a}, -C(=O)-O-R^{2a}, -C(=O)-N(-R^{2a}, -R^{3a}), and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

n is an integer of 0-2;

R^{2a} and R^{3a} are independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{1-4}alkyl-(carbocyclic aryl);

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

halo, -C_{1-4}alkyl, -CN, -NO_2, -N(-R^{2b}, -R^{3b}), -C(=O)-N(-R^{2b}, -R^{3b}), -S(=O)$_2$-N(-R^{2b}, -R^{3b}), -S(=O)$_2$-R^{2b}, -CF_3, -O-R^{2b}, -O-CH_2-CH_2-O-R^{2b}, -O-CH_2-C(=O)-O-R^{2b}, -N(-R^{2b})-CH_2-CH_2-O-R^{2b}, -N(-CH_2-CH_2-O-R^{2b})$_2$, -N(-R^{2b})-C(=O)-R^{3b}, -N(-R^{2b})-S(=O)$_2$-R^{3b}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

each R^{2b} and R^{3b} is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{1-4}alkyl-(carbocyclic aryl);

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, -C_{1-4}alkyl, -CN, -NO_2, -$(CH_2)_z$-N(-R^{2c}, -R^{3c}), -C(=O)-N(-R^{2c}, -R^{3c}), -C(=NH)-N(-R^{2c}, -R^{3c}), -C(=NMe)-N(-R^{2c}, -R^{3c}), -S(=O)$_2$-N(-R^{2c}, -R^{3c}), -S(=O)$_2$-R^{2c},

-S(=O)$_2$-O H, -CF_3, -O-R^{2c}, -O(-CH_2)$_z$-O-R^{2c}, -O(-CH_2)$_z$-C(=O)-O-R^{2c}, -N(-R^{2c}), -O(-CH_2)$_z$-O-R^{2c}, -N[(-CH_2)$_z$-O-R^{2c}]$_2$, -(CH_2)$_z$-N(-R^{2c})-C(=O)-R^{3c}, -(CH_2)$_z$-N(-R^{2c})-S(=O)$_2$-R^{3c}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{1-4}alkyl-(carbocyclic aryl);

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

26. (Currently amended) The ~~A~~ method ~~for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound~~ of claim ~~2~~ 22

wherein:

A is selected from the group consisting of:

phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, C_{1-4}alkyl, -CN, -C(=O)-N(R^2, R^3), -NO_2, -SO_2N(R^2, R^3), -SO_2R^2, -(CH_2)$_m$NR^2R^3, -(CH_2)$_m$-C(=NR^3)-R^2, -(CH_2)$_m$-C(=NR^2)-N(R^2,R^3), -(CH_2)$_m$-N(R^2)-C(=NR^2)-N(R^2,R^3), -(CH_2)$_m$NR^2-C_{3-6}heterocyclics, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl, -CF_3, -OR^2, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{0-4}alkyl-(carbocyclic aryl);

m is an integer of 0-2;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

halo, -C_{1-4}alkyl, -CN, -NO_2, -$(CH_2)_n$-N(-R^{2a}, -R^{3a}), -S(=O)$_2$-N(-R^{2a}, -R^{3a}), -S(=O)$_2$-R^{2a}, -CF_3, -$(CH_2)_n$-OR^{2a}, -C(=O)-O-R^{2a}, -C(=O)-N(-R^{2a}, -R^{3a}), and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

n is an integer of 0-2;

R^{2a} and R^{3a} are independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{1-4}alkyl-(carbocyclic aryl);

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

halo, -C_{1-4}alkyl, -CN, -NO_2, -N(-R^{2b}, -R^{3b}), -C(=O)-N(-R^{2b}, -R^{3b}), -S(=O)$_2$-N(-R^{2b}, -R^{3b}), -S(=O)$_2$-R^{2b}, -CF_3, -O-R^{2b}, -O-CH_2-CH_2-O-R^{2b}, -O-CH_2-C(=O)-O-R^{2b}, -N(-R^{2b})-CH_2-CH_2-O-R^{2b}, -N(-CH_2-CH_2-O-R^{2b})$_2$, -N(-R^{2b})-C(=O)-R^{3b}, -N(-R^{2b})-S(=O)$_2$-R^{3b}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

each R^{2b} and R^{3b} is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{1-4}alkyl-(carbocyclic aryl);

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, $-C_{1-4}$alkyl, -CN, $-NO_2$, $-(CH_2)_z-N(-R^{2c}, -R^{3c})$, $-C(=O)-N(-R^{2c}, -R^{3c})$, $-C(=NH)-N(-R^{2c}, -R^{3c})$, $-C(=NMe)-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-R^{2c}$, $-S(=O)_2-OH$, $-CF_3$, $-O-R^{2c}$, $-O(-CH_2)_z-O-R^{2c}$, $-O(-CH_2)_z-C(=O)-O-R^{2c}$, $-N(-R^{2c})$, $-O(-CH_2)_z-O-R^{2c}$, $-N[(-CH_2)_z-O-R^{2c}]_2$, $-(CH_2)_z-N(-R^{2c})-C(=O)-R^{3c}$, $-(CH_2)_z-N(-R^{2c})-S(=O)_2-R^{3c}$, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, $-C_{1-4}$alkyl and $-C_{1-4}$alkyl-(carbocyclic aryl);

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

27. (Currently amended) The method of claim **26** ~~10~~, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.

28. (Canceled)

29. (Currently amended) A pharmaceutical composition **of claim 21** ~~for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 3~~

wherein:

A is selected from the group consisting of:



;

Q is a direct link;

D is selected from the group consisting of:



;

E is -NH-C(=O)-;

G has the following formula:



;

each R^{1b} is a member independently selected from the group consisting of:

-H, -Me, -CF_3, -F, -Cl, -Br, -SO_2Me, -CN, -$CONH_2$, -$CONMe_2$, -NH_2, -NO_2, -NHCOMe, -$NHSO_2Me$, -CH_2NH_2 and -CO_2H;

J is a direct link;

X is selected from the group consisting of:




MeO2S
F
MeO2S
Cl
MeO2S
Br
MeO2S
F
MeO2S
Cl
MeO2S
Br
H2NO2S
F
H2NO2S
Cl
H2NO2S
Br
H2NO2S
F
H2NO2S
Cl
H2NO2S
Br
O2N
F
O2N
Cl
O2N
Br
O2N
F
O2N
Cl
O2N
Br
NC
F
NC
Cl
NC
Br
NC
F
NC
Cl
NC
Br
H2NOC
F
H2NOC
Cl
H2NOC
Br
H2NOC
F
H2NOC
Cl
H2NOC
Br


HO F
HO Cl
HO Br
HO F
HO Cl
HO Br
MeO F
MeO Cl
MeO Br
MeO F
MeO Cl
MeO Br
H2N F
H2N Cl
H2N Br
H2N F
H2N Cl
H2N Br
MeO2S F
MeO2S F
MeO2S Br
MeO2S F
MeO2S Cl
MeO2S Cl
MeO2S Br
MeO2S F
MeO2S Br
MeO2S Cl
MeO2S Br
H2NO2S F
H2NO2S F
H2NO2S Cl
H2NO2S Cl
H2NO2S Br
H2NO2S F
H2NO2S Br
H2NO2S Cl
H2NO2S Br
O2N F
O2N F
O2N Cl
O2N F
O2N Cl
O2N Br
O2N F
O2N Cl
O2N Cl
O2N Br
O2N F
O2N Br
O2N Br
O2N Br
NC F
NC F
NC Cl
NC F
NC Br
NC F



;

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof

30. (Currently amended) **The** ~~A~~ method ~~**for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound**~~ of claim ~~3~~ **22**

wherein:

A is selected from the group consisting of:



;

Q is a direct link;

D is selected from the group consisting of:



;

E is -NH-C(=O)-;

G has the following formula:



;

each R^{1b} is a member independently selected from the group consisting of:

-H, -Me, -CF_3, -F, -Cl, -Br, -SO_2Me, -CN, -$CONH_2$, -$CONMe_2$, -NH_2, -NO_2, -NHCOMe, -$NHSO_2$Me, -CH_2NH_2 and -CO_2H;

J is a direct link;

X is selected from the group consisting of:


MeO2S
H2NO2S
O2N
H2N
HO
H2N
NH
Br
H2N
O
HO
O
MeO
O
F
NC
F
Cl
Cl
Cl
F
F
Cl
Br
Cl
F
Cl
Br
F
F
F
Br
Br
Br
F
Cl
F
Br
NH2
Br
F
F
F
F
Cl
OH
OMe
NH2


MeO2S F
MeO2S Cl
MeO2S Br
MeO2S F
MeO2S Cl
MeO2S Br
H2NO2S F
H2NO2S Cl
H2NO2S Br
H2NO2S F
H2NO2S Cl
H2NO2S Br
O2N F
O2N Cl
O2N Br
O2N F
O2N Cl
O2N Br
NC F
NC Cl
NC Br
NC F
NC Cl
NC Br
H2NOC F
H2NOC Cl
H2NOC Br
H2NOC F
H2NOC Cl
H2NOC Br


HO F
HO Cl
HO Br
HO F
HO Cl
HO Br
MeO F
MeO Cl
MeO Br
MeO F
MeO Cl
MeO Br
H2N F
H2N Cl
H2N Br
H2N F
H2N Cl
H2N Br
MeO2S F
MeO2S F
MeO2S Br F
MeO2S F Cl
MeO2S Cl Cl
MeO2S Br Cl
MeO2S F Br
MeO2S Cl Br
MeO2S Br Br
H2NO2S F F
H2NO2S Cl F
H2NO2S Br F
H2NO2S F Cl
H2NO2S Cl Cl
H2NO2S Br Cl
H2NO2S F Br
H2NO2S Cl Br
H2NO2S Br Br
O2N F F
O2N Cl F
O2N Br F
O2N F Cl
O2N Cl Cl
O2N Br Cl
O2N F Br
O2N Cl Br
O2N Br Br
NC F F
NC Cl F
NC Br F



;

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

31. (Original) The method of claim 30, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation,

thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.

32. (Canceled)

33. (Currently amended) A pharmaceutical composition **of claim 21** ~~for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 4~~

wherein:

A is phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, C_{1-4}alkyl, -CN, -C(=O)-N(R^2, R^3), $-NO_2$, $-SO_2N(R^2, R^3)$, $-SO_2R^2$, $-(CH_2)_mNR^2R^3$, $-(CH_2)_m$-C(=NR^3)-R^2, $-(CH_2)_m$-C(=NR^2)-N(R^2,R^3), $-(CH_2)_m$-N(R^2)-C(=NR^2)-N(R^2,R^3), $-(CH_2)_mNR^2$-C_{3-6}heterocyclics, C_{2-6}alkenyl, C_{2-6}alkynyl, C_{3-8}cycloalkyl, C_{0-4}alkylC_{3-8}cycloalkyl, $-CF_3$, $-OR^2$, and a 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from N, O and S;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H, -C_{1-4}alkyl and -C_{0-4}alkyl-(carbocyclic aryl);

m is an integer of 0-2;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

halo, $-C_{1-4}$alkyl, -CN, $-NO_2$, $-(CH_2)_n-N(-R^{2a}, -R^{3a})$, $-S(=O)_2-N(-R^{2a}, -R^{3a})$, $-S(=O)_2-R^{2a}$, $-CF_3$, $-(CH_2)_n-OR^{2a}$, $-C(=O)-O-R^{2a}$, $-C(=O)-N(-R^{2a}, -R^{3a})$, and a 5-6 membered aromatic heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

n is an integer of 0-2;

R^{2a} and R^{3a} are independently selected from the group consisting of:

-H, $-C_{1-4}$alkyl and $-C_{1-4}$alkyl-(carbocyclic aryl);

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

halo, $-C_{1-4}$alkyl, -CN, $-NO_2$, $-N(-R^{2b}, -R^{3b})$, $-C(=O)-N(-R^{2b}, -R^{3b})$, $-S(=O)_2-N(-R^{2b}, -R^{3b})$, $-S(=O)_2-R^{2b}$, $-CF_3$, $-O-R^{2b}$, $-O-CH_2-CH_2-O-R^{2b}$, $-O-CH_2-C(=O)-O-R^{2b}$, $-N(-R^{2b})-CH_2-CH_2-O-R^{2b}$, $-N(-CH_2-CH_2-O-R^{2b})_2$, $-N(-R^{2b})-C(=O)-R^{3b}$, $-N(-R^{2b})-S(=O)_2-R^{3b}$, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

each R^{2b} and R^{3b} is a member independently selected from the group consisting of:

-H, $-C_{1-4}$alkyl and $-C_{1-4}$alkyl-(carbocyclic aryl);

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, $-C_{1-4}$alkyl, -CN, $-NO_2$, $-(CH_2)_z-N(-R^{2c}, -R^{3c})$, $-C(=O)-N(-R^{2c}, -R^{3c})$, $-C(=NH)-N(-R^{2c}, -R^{3c})$, $-C(=NMe)-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-R^{2c}$,

-S(=O)$_2$-O H, -CF$_3$, -O-R^{2c}, -O(-CH$_2$)$_z$-O-R^{2c}, -O(-CH$_2$)$_z$-C(=O)-O-R^{2c}, -N(-R^{2c}), -O(-CH$_2$)$_z$-O-R^{2c}, -N[(-CH$_2$)$_z$-O-R^{2c}]$_2$, -(CH$_2$)$_z$-N(-R^{2c})-C(=O)-R^{3c}, -(CH$_2$)$_z$-N(-R^{2c})-S(=O)$_2$-R^{3c}, and a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from N, O and S;

z is an integer of 0-4;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, -C$_{1-4}$alkyl and -C$_{1-4}$alkyl-(carbocyclic aryl);

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

26. (Currently amended) The ~~A~~ method ~~for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound~~ of claim ~~2~~ 22

wherein:

A is phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, -CN, -SO$_2$N(R^2, R^3), -SO$_2$R^2, and -CH$_2$NR^{2}R^3;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H and -C$_{1-4}$alkyl;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

-H and halo;

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

- Me, -Et, $-CF_3$, $-C(=O)-NH_2$, $-NH_2$, -NH-(C=O)-Me, $-NH-S(=O)_2$-Me, -SMe, $-S(=O)$-Me and halo;

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, OH, -OMe, $-NH_2$, -CN, $-NO_2$, $-CH_2OH$, $-C_{1-5}$alkyl, $-C(=O)-N(-R^{2c}, -R^{3c})$, $-C(=NH)-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-N(-R^{2c}, -R^{3c})$, $-S(=O)_2-R^{2c}$, $-S(=O)_2-OH$, $-CF_3$, 2-imidazolin-2-yl and 1-methyl-2-imidazolin-2-yl;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, -OH, $-NH_2$ and $-C_{1-4}$alkyl;

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

34. (Currently amended) **The** ~~A~~ method ~~for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound~~ of claim ~~4~~ **22**

wherein:

A is phenyl, which is substituted with 0-2 R^1 groups;

each R^1 is a member independently selected from the group consisting of:

halo, -CN, $-SO_2N(R^2, R^3)$, $-SO_2R^2$ and $-CH_2NR^2R^3$;

each R^2 and R^3 is a member independently selected from the group consisting of:

-H and -C_{1-4}alkyl;

Q is a direct link;

D is phenyl, which is substituted with 0-2 R^{1a} groups;

each R^{1a} is a member independently selected from the group consisting of:

-H and halo;

E is -NH-C(=O)-;

G is a pyrazole ring substituted with 0-2 R^{1b} groups;

each R^{1b} is a member independently selected from the group consisting of:

- Me, -Et, -CF_3, -C(=O)-NH_2, -NH_2, -NH-(C=O)-Me, -NH-S(=O)$_2$-Me, -SMe, -S(=O)-Me and halo;

J is a direct link;

X is a naphthyl, which is substituted with 0-3 R^{1c} groups;

each R^{1c} is a member independently selected from the group consisting of:

halo, OH, -OMe, -NH_2, -CN, -NO_2, -CH_2OH, -C_{1-5}alkyl, -C(=O)-N(-R^{2c}, -R^{3c}), -C(=NH)-N(-R^{2c}, -R^{3c}), -S(=O)$_2$-N(-R^{2c}, -R^{3c}), -S(=O)$_2$-R^{2c}, -S(=O)$_2$-OH, -CF_3, 2-imidazolin-2-yl and 1-methyl-2-imidazolin-2-yl;

each R^{2c} and R^{3c} is a member independently selected from the group consisting of:

-H, -OH, -NH_2 and -C_{1-4}alkyl;

or all pharmaceutically acceptable diastereomers, enantiomers or mixtures thereof, salts, hydrates or solvates thereof.

35. (Original) The method of claim 34, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.

36. (Canceled)

37. (New) A pharmaceutical composition of claim 21

wherein the compound has the following formula:



R^1 is selected from the group consisting of:

$-S(=O)_2-NH_2$, $-S(=O)_2-Me$, $-CH_2NH_2$, and $-CH_2NMe_2$;

R^{1a} is selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1c1} is independently selected from the group consisting of:

-H, -F, -Cl, -Br, $-NH_2$, -OH, $-SO_2Me$, $-SO_2Et$, $-SO_2NH_2$, $-NO_2$, -CN, $-CONH_2$ and $-CH_2OH$;

R^{1c2} is independently selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1c3} is independently selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1b} is selected from the group consisting of:

-H, $-CH_3$ and $-CF_3$.

38. (New) The method of claim-22

wherein the compound has the following formula:



R^1 is selected from the group consisting of:

$-S(=O)_2-NH_2$, $-S(=O)_2-Me$, $-CH_2NH_2$, and $-CH_2NMe_2$;

R^{1a} is selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1c1} is independently selected from the group consisting of:

-H, -F, -Cl, -Br, $-NH_2$, -OH, $-SO_2Me$, $-SO_2Et$, $-SO_2NH_2$, $-NO_2$, -CN, $-CONH_2$ and $-CH_2OH$;

R^{1c2} is independently selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1c3} is independently selected from the group consisting of:

-H, -F, -Cl and -Br;

R^{1b} is selected from the group consisting of:

-H, $-CH_3$ and $-CF_3$.

40. (New) The method of claim 39, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.